Why all the fuss about fluoride? Who was complaining about our water supply?
Why all the fuss about fluoride? Who was complaining about our water supply? | Our View
Show Caption
Hide Caption
The truth about fluoride
Fluoride is present in dental products like toothpaste, protecting teeth from cavities and preventing bacteria in the mouth. It is also added to public water supplies.
unbranded - Lifestyle
Like radon in our basements and alar in our apples from a few years back, Treasure Coast communities are confronting a "new" potential problem that's both invisible and poorly understood:
Fluoride in our water supply.
Some, but not all, utility companies in our region have been adding fluoride to water as a common practice. Fluoride is supposed to help prevent tooth decay.
People who brush their teeth and regularly visit a dentist might not need it, but the thinking has been drinking water with small amounts of fluoride could help people who weren't taking proper care of their teeth.
Until recently, when the thinking changed. Florida Surgeon General Joseph Ladapo's office issued a warning last year about possible health risks associated with fluoridated drinking water.
A U.S. District Court in California ruled even small amounts of fluoride — 0.7 milligrams per liter — could carry health risks. According to Ladapo, these include "children reducing IQ, cognitive impairment and attention deficit hyperactivity disorder."
The Stuart City Commission voted swiftly to stop adding fluoride to its tap water, with other local governments following suit or considering similar actions.
Other parts of Martin County are served by providers that weren't adding fluoride.
Port St. Lucie and St. Lucie West also decided to stop adding fluoride, while Fort Pierce, which also provides water to unincorporated St. Lucie County, is studying the issue.
Drill into the research a little bit
More: Trump, Biden undermine justice with Florida Turnpike killers, Jan. 6 rioters | Editorial
More: Stuart, Martin moms-to-be must travel to Port St. Lucie, Jupiter to deliver? | Our View
Since Robert F. Kennedy Jr., President Donald Trump's nominee for Health and Human Services secretary, is against fluoridation, it's likely the discussions about fluoride bans are going to continue in local council and commission chambers for a while.
There's a "monkey see, monkey do" aspect to what's happening now. Local governments are in a rush to become part of the anti-fluoridation trend, even though it's not clear how this issue bubbled to the surface of public consciousness.
If fluoride has potentially harmful effects, it's certainly reasonable to find out more about what those effects are and if they outweigh the potential benefits.
It's reminiscent of the vaccine debate from a few years ago, when some saw potentially harmful side effects as reason to avoid getting vaccinated against COVID. Even if catching a severe case of COVID was an even greater risk for certain people.
Scientific discovery is often a balancing act. Scientists do research and find potential health benefits from drinking a couple of glasses of red wine a day. Then, they do some more research and find out there are health risks associated with that habit, too.
Deal in facts, not political talking points
The key is trying to find the right balance. Do the risks truly outweigh the rewards? Snap decisions shouldn't be based on a single study someone cherry-picked to match a particular set of beliefs.
If scientific consensus shows fluoridation is more bad than good, then the chemical shouldn't be added to public water supplies.
It doesn't feel like there's enough data out there to make such a determination yet. Much more needs to be shared with the public about the studies showing harmful effects — and how they square with earlier ones showing the benefits of fluoridation.
This shouldn't be about politics. Banning fluoride shouldn't be done to curry favor with Trump, Gov. Ron DeSantis or anyone else.
This is a public safety matter and should be treated as such.
If fluoride opponents have learned about dangers from the chemical that haven't been widely known, then they shouldn't mind sharing the information with others who aren't "in the know."
Fluoride bans should be able to stand up to careful scrutiny if they're about protecting people's health.
If the bans are being discussed for political reasons, then it's one of the more cynical endeavors in an age of cynical political endeavors.
It's one thing to try to render political opponents toothless in a metaphorical sense, but not in a literal one.
So there's new research available on fluoride? Let's discuss it in open community forums and decide if that research merits changes to longstanding practices.
After those discussions are over, hopefully, we'll all still be able to smile and remain friends.
Editorials published by TCPalm/Treasure Coast Newspapers are decided collectively by its editorial board. To respond to this editorial with a letter to the editor, email up to 300 words to TCNLetters@TCPalm.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Politico
25 minutes ago
- Politico
AI, the disruptor-in-chief
FORWARD THINKING Artificial intelligence is upending how industries function and it's coming for scientific research next. Rene Caissie, an adjunct professor at Stanford University, wants AI to conduct research. In 2021, he started a company, that lets public health departments, researchers and life sciences companies pose research questions and receive answers immediately. And, unlike many AI systems, Caissie told Ruth, the AI explains those answers by showing the data its results are based on. 'It used to be hard to do research,' he said, explaining that it takes a lot of time for researchers to get access to and organize data in order to answer basic scientific questions. Manual data analysis can also take months. The company is now partnering with HealthVerity, a provider of real-world health data, to build up its data sources. In turn, HealthVerity will offer Medeloop's research platform to its clients. The company has worked with the Food and Drug Administration, the National Institutes of Health, and the Centers for Disease Control and Prevention in the past. Caissie says the New York City Department of Health and Mental Hygiene is already using Medeloop's AI to run public health analyses. Why it matters: Public health departments receive huge amounts of data on human health from a variety of sources. But prepping that information and analyzing it can be onerous. Having access to a research platform like Medeloop could give public health departments and academic medical centers much faster insight into trends and in turn enable them to respond more quickly. How it works: Medeloop's AI is designed to think like a researcher. In a demo, Medeloop strategist John Ayers asked the bot how many people received a first-time autism diagnosis, broken down by age, race and sex, and what trends were visible with that data. He wanted the AI to only include people who had had interactions with a doctor for at least two years prior to diagnosis. The platform returned a refined query to improve results and a suggestion for what medical codes to use to identify the right patients for inclusion in the study. It delivered a trial design that looked at a cohort of 799,560 patients with new autism diagnoses between January 2015 and December 2024. Medeloop's AI showed that 70 percent of new autism diagnoses were for males. A monthly trends report found that, outside of a dip during the Covid-19 pandemic, new autism diagnoses have been on the rise, particularly among 5-11 year olds since 2019. Though Medeloop doesn't determine the cause of autism, the ease with which users can obtain answers could help speed up the pace of research. One of the platform's key innovations is its use of a federated network of data. Medeloop's new deal with HealthVerity will raise the platform's de-identified and secure patient records to 200 million. Notably, the data never leaves the health system, which increases security. Instead, Medeloop sends its AI to wherever the data is stored, analyzes it there and then returns the results to the platform. WELCOME TO FUTURE PULSE This is where we explore the ideas and innovators shaping health care. Scientists are making cover art and figures for research papers using artificial intelligence. Now illustrators are calling them out, Nature's Kamal Nahas reports. Share any thoughts, news, tips and feedback with Danny Nguyen at dnguyen@ Carmen Paun at cpaun@ Ruth Reader at rreader@ or Erin Schumaker at eschumaker@ Want to share a tip securely? Message us on Signal: Dannyn516.70, CarmenP.82, RuthReader.02 or ErinSchumaker.01. TECH MAZE Large language models like ChatGPT and Claude generate inferior mental health care treatment when presented with data about a patient's race, according to a study published this week in npj Digital Medicine. The findings: Researchers from Cedars-Sinai, Stanford University and the Jonathan Jaques Children's Cancer Institute tested how artificial intelligence would produce diagnoses for psychiatric patient cases under three conditions: race neutral, race implied and race explicitly stated using four models. They included the commercially available large language models ChatGPT, Claude and Gemini, as well as NewMes-15, a local model that can run on personal devices without cloud services. The researchers then asked clinical and social psychologists to evaluate the findings for bias. Most LLMs recommended dramatically different treatments for African American patients compared with others, even when they had the same psychiatric disorder and patient profile outside of race. The LLMs also proposed inferior treatments when they were made aware of a patient's race, either explicitly or implicitly. The biases likely come from the way LLMs are trained, the researchers wrote, and it's unclear how developers can mitigate those biases because 'traditional bias mitigation strategies that are standard practice, such as adversarial training, explainable AI methods, data augmentation and resampling may not be enough,' the researchers wrote. Why it matters: The study is one of the first evaluations of racial bias on psychiatric diagnoses across multiple LLMs. It comes as people increasingly turn to chatbots like ChatGPT for mental health advice and medical diagnoses. The results underscore the nascent technology's flaws. What's next: The study was small — only 10 cases were examined — which might not fully capture the consistency or extent of bias. The authors suggest that future studies could focus on a single condition with more cases for deeper analysis.
Los Angeles Times
an hour ago
- Los Angeles Times
Anaheim Regional Medical Center nurses' union wins pay boost, security upgrades
Registered nurses who work at the Anaheim Regional Medical Center voted to ratify their first-ever labor contract with the hospital on Wednesday night, an agreement they claim will improve patient care. As negotiations carried on, safety remained a top priority for nurses represented by SEIU Local 121RN. The union in April held an info picket outside of the hospital to draw attention to such issues. In the past, nurses and their aides have screened people for weapons and drugs at the hospital's emergency room entrance. While nurses did not gain the walk-through metal detectors they pushed for in bargaining, the hospital has agreed to staff security guards with metal detector wands at different entry points within six months to a year. Security staff will also take over bag searches and provide identification for visitors. 'That's something we're not responsible for anymore,' said Liza Lorenzo, a telemetry nurse who has worked at the hospital for the past 15 years. 'We have more time to do bedside care, as opposed to going through people's belongings, which was not safe for us, as well.' When reached, a spokesperson for AHMC Healthcare, the company that owns the hospital, declined to comment on the contract. The security changes come before Assembly Bill 2975, which the union advocated for and requires hospitals throughout the state to have weapons detection screening policies by March 2027. Nurses also won a minimum 19% pay raise over the four years of the contract. The salary boost comes with additional measures to ensure there are four nurses for every patient at a specialty unit, a ratio mandated by state law. For telemetry units, the nurse-patient ratio is five-to-one. During the pandemic, Lorenzo claimed that the hospital stretched its nurse-to-patient ratios beyond their limits but nurses now have protections in place to hold management accountable. 'We made sure that we have a resource nurse for every five nurses or more,' said Lorenzo, who helped negotiate the contract. 'If there's five nurses in the unit, we will have a resource nurse dedicated for that unit alone. Obviously, better staffing leads to faster response, reduces medical errors and prevents staff burnout.' Nurses are hopeful that the boosted salaries and ratio protections will go a long way toward addressing what they called inadequate staffing at the hospital. The union also proposed forming a pandemic task force following the experience of the COVID-19 pandemic that overwhelmed hospitals in Orange County. The contract guarantees that nurses will have enough personal protective equipment for three months while following U.S. Center for Disease Control and Prevention guidelines. 'We're more prepared in the case of another pandemic, as opposed to just scrambling,' Lorenzo said. As nurses also complained about broken-down MRI machines and the lack of running hot water at times, the hospital has also pledged to make timely repairs to medical equipment while addressing other maintenance issues. Lorenzo beamed with pride when speaking about critical provisions of the newly ratified contract, which arrived in less than one year's time since safety concerns first prompted nurses to unionize in August. 'Our efforts have paid off,' she said. 'Now we have our first contract. This is not only for us, but also for our patients and the community.'
Indianapolis Star
3 hours ago
- Indianapolis Star
Moderna Announces Update on Investigational Pandemic Influenza Program
Phase 1/2 H5 avian flu vaccine study shows positive interim results Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines CAMBRIDGE, MA / ACCESS Newswire Moderna, Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study (NCT05972174) evaluating the safety and immunogenicity of its investigational pandemic influenza vaccine, mRNA-1018, in approximately 300 healthy adults aged 18 years and older. The interim results focus on a vaccine candidate targeting the H5 avian influenza virus subtype. The Company had previously expected to advance the program to late-stage development with the U.S. Department of Health and Human Services (HHS); however, today Moderna received notice that HHS will terminate the award for the late-stage development and right to purchase pre-pandemic influenza vaccines. 'While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis of the Phase 1/2 study of our H5 avian flu vaccine and we will explore alternative paths forward for the program,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'These clinical data in pandemic influenza underscore the critical role mRNA technology has played as a countermeasure to emerging health threats.' The Phase 1/2 study evaluated a two-dose regimen of Moderna's investigational avian influenza vaccine. mRNA-1018 demonstrated a rapid, potent and durable immune response. At baseline, pre-existing immunity was minimal, with only 2.1% of participants showing hemagglutination inhibition (HAI) antibody titers ≥1:40, an HAI titer considered to correlate with protection. At Day 43, three weeks after the second vaccination, 97.8% of participants achieved titers ≥1:40 with a 44.5-fold increase of titers from baseline. The investigational vaccine was generally well-tolerated, with no dose-limiting tolerability concerns observed. Most solicited adverse reactions were Grade 1 or 2 and did not increase significantly with number of doses or between first and second doses. Further data is expected to be submitted for presentation at an upcoming scientific meeting. Moderna will explore alternatives for late-stage development and manufacturing of the H5 program consistent with the Company's strategic commitment to pandemic preparedness. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the clinical development of mRNA-1018, the safety and immunogenicity data from the Phase 1/2 study; the cancellation of the development contract for Moderna's pandemic flu program by the U.S. Department of Health and Human Services; and the exploration of alternative paths for development of the vaccine program. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading 'Risk Factors' in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 SOURCE: Moderna, Inc. View the original press release on ACCESS Newswire
